LY4214835
Phase 1Small molecule
Eli LillyLY4214835 is one of 18 small molecule programs targeting Neoplasms. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in Neoplasms
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 3
Taxol
TevaPhase 3
Xtandi
AstellasPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Alimta
GGynecologic Oncology Group
Phase 3
Jakafi
IncytePhase 1
Keytruda
Merck & Co.Phase 1
Dostarlimab
IncytePhase 1
Ojjaara
GGlaxo Dba Glaxosmithkline
Phase 1
Cetrelimab
Johnson & JohnsonPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY4214835. EMBL-EBI & Wellcome Sanger Institute.
- [4]